/MDGL
MDGL Stock - Madrigal Pharmaceuticals, Inc.
Healthcare|BiotechnologyNASDAQ
$493.90-3.26%
$16.63 (-3.26%) • Jan 13
80
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.BUY
High Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.60
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.100
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+33.5%upside
Target: $659.36
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for MDGL
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$488.96 – $498.84
TARGET (TP)$659.56
STOP LOSS$454.39
RISK/REWARD1:4.2
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta-1.01
52W High$615.00
52W Low$265.00
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $180.13M | N/A | N/A | N/A | N/A |
| Gross Profit | $173.90M | N/A | N/A | N/A | $-471,000 |
| Gross Margin | 96.5% | N/A | N/A | N/A | N/A |
| Operating Income | $-497,875,000 | $-380,496,000 | $-293,571,000 | $-242,482,000 | $-206,320,000 |
| Net Income | $-465,892,000 | $-373,630,000 | $-295,350,000 | $-241,846,000 | $-202,244,000 |
| Net Margin | -258.6% | N/A | N/A | N/A | N/A |
| EPS | $-21.90 | $-19.99 | $-17.23 | $-14.63 | $-13.09 |
Company Overview
Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. Its lead product candidate is resmetirom, a liver-directed selective thyroid hormone receptor-ß agonist, which is in Phase III clinical trials for the treatment of non-alcoholic steatohepatitis. The company also develops MGL-3745, a backup compound to resmetirom. It has research, development, and commercialization agreement with Hoffmann-La Roche. Madrigal Pharmaceuticals, Inc. is headquartered in West Conshohocken, Pennsylvania.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
MDGLBeat Rate
50%
Last 18 quarters
Avg Surprise
-4.6%
EPS vs Estimate
Beats / Misses
9/9
Last 12 quarters
Latest EPS
$-5.08
Q4 2025
EPS Surprise History
Q1 24
-6.8%
$-5.68vs$-5.32
Q2 24
-21.8%
$-7.38vs$-6.06
Q3 24
+6.0%
$-7.10vs$-7.55
Q4 24
+29.1%
$-4.92vs$-6.94
Q1 25
+37.3%
$-2.71vs$-4.32
Q2 25
+8.3%
$-3.32vs$-3.62
Q3 25
+45.4%
$-1.90vs$-3.48
Q4 25
-149.4%
$-5.08vs$-2.04
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q2 2026 | Apr 29, 2026 | — | — | — | — |
Q1 2026 | Feb 25, 2026 | $0.08 | — | — | — |
Q4 2025 | Nov 4, 2025 | $-2.04 | $-5.08 | -149.4% | ✗ MISS |
Q3 2025 | Aug 5, 2025 | $-3.48 | $-1.90 | +45.4% | ✓ BEAT |
Q2 2025 | May 1, 2025 | $-3.62 | $-3.32 | +8.3% | ✓ BEAT |
Q1 2025 | Feb 26, 2025 | $-4.32 | $-2.71 | +37.3% | ✓ BEAT |
Q4 2024 | Oct 31, 2024 | $-6.94 | $-4.92 | +29.1% | ✓ BEAT |
Q3 2024 | Aug 7, 2024 | $-7.55 | $-7.10 | +6.0% | ✓ BEAT |
Q2 2024 | May 7, 2024 | $-6.06 | $-7.38 | -21.8% | ✗ MISS |
Q1 2024 | Feb 28, 2024 | $-5.32 | $-5.68 | -6.8% | ✗ MISS |
Q4 2023 | Nov 6, 2023 | $-4.78 | $-5.34 | -11.7% | ✗ MISS |
Q3 2023 | Aug 8, 2023 | $-4.47 | $-4.69 | -4.9% | ✗ MISS |
Q2 2023 | May 9, 2023 | $-4.98 | $-4.23 | +15.1% | ✓ BEAT |
Q1 2023 | Feb 23, 2023 | $-4.41 | $-4.98 | -12.9% | ✗ MISS |
Q4 2022 | Nov 3, 2022 | $-4.05 | $-4.75 | -17.3% | ✗ MISS |
Q3 2022 | Aug 4, 2022 | $-3.76 | $-4.14 | -10.1% | ✗ MISS |
Q2 2022 | May 9, 2022 | $-3.75 | $-3.36 | +10.4% | ✓ BEAT |
Q1 2022 | Feb 24, 2022 | $-3.92 | $-3.78 | +3.6% | ✓ BEAT |
Q4 2021 | Nov 4, 2021 | $-3.89 | $-3.79 | +2.6% | ✓ BEAT |
Q3 2021 | Aug 5, 2021 | $-3.55 | $-3.72 | -4.8% | ✗ MISS |
Latest News
Loading news...
Frequently Asked Questions about MDGL
What is MDGL's current stock price?
Madrigal Pharmaceuticals, Inc. (MDGL) is currently trading at $493.90 per share. The stock has moved -3.26% today.
What is the analyst price target for MDGL?
The average analyst price target for MDGL is $659.56, based on 1 analyst.
What sector is Madrigal Pharmaceuticals, Inc. in?
Madrigal Pharmaceuticals, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is MDGL's market cap?
Madrigal Pharmaceuticals, Inc. has a market capitalization of $10.95 billion, making it a large-cap company.
Does MDGL pay dividends?
No, Madrigal Pharmaceuticals, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorABVX
Abivax S.A.
$119.64
Mkt Cap: $7.8B
BAX
Baxter International Inc.
$19.65
Mkt Cap: $10.1B
BMRN
BioMarin Pharmaceutical Inc.
$55.20
Mkt Cap: $10.6B
CAI
Caris Life Sciences, Inc.
$26.40
Mkt Cap: $7.4B
EXEL
Exelixis, Inc.
$44.08
Mkt Cap: $11.8B
JAZZ
Jazz Pharmaceuticals plc
$162.43
Mkt Cap: $9.9B
MRNA
Moderna, Inc.
$39.60
Mkt Cap: $15.5B
RNA
Avidity Biosciences, Inc.
$72.43
Mkt Cap: $9.5B
RYTM
Rhythm Pharmaceuticals, Inc.
$107.80
Mkt Cap: $7.2B
TECH
Bio-Techne Corporation
$66.36
Mkt Cap: $10.4B
Explore stocks similar to MDGL for comparison